S&P 500   3,929.82 (-0.29%)
DOW   33,558.44 (-0.11%)
QQQ   280.92 (-0.27%)
AAPL   141.22 (-1.18%)
MSFT   244.65 (-0.19%)
META   113.87 (-0.22%)
GOOGL   95.15 (-1.89%)
AMZN   88.40 (+0.17%)
TSLA   173.08 (-3.75%)
NVDA   160.67 (+0.50%)
NIO   12.61 (-4.76%)
BABA   88.56 (-3.16%)
AMD   69.94 (-0.47%)
T   19.32 (+0.78%)
MU   53.50 (-0.34%)
CGC   3.22 (-10.80%)
F   13.14 (-1.05%)
GE   85.47 (+0.22%)
DIS   92.00 (-0.31%)
AMC   6.10 (-9.63%)
PYPL   74.31 (+2.88%)
PFE   50.41 (+1.41%)
NFLX   306.90 (+0.44%)
S&P 500   3,929.82 (-0.29%)
DOW   33,558.44 (-0.11%)
QQQ   280.92 (-0.27%)
AAPL   141.22 (-1.18%)
MSFT   244.65 (-0.19%)
META   113.87 (-0.22%)
GOOGL   95.15 (-1.89%)
AMZN   88.40 (+0.17%)
TSLA   173.08 (-3.75%)
NVDA   160.67 (+0.50%)
NIO   12.61 (-4.76%)
BABA   88.56 (-3.16%)
AMD   69.94 (-0.47%)
T   19.32 (+0.78%)
MU   53.50 (-0.34%)
CGC   3.22 (-10.80%)
F   13.14 (-1.05%)
GE   85.47 (+0.22%)
DIS   92.00 (-0.31%)
AMC   6.10 (-9.63%)
PYPL   74.31 (+2.88%)
PFE   50.41 (+1.41%)
NFLX   306.90 (+0.44%)
S&P 500   3,929.82 (-0.29%)
DOW   33,558.44 (-0.11%)
QQQ   280.92 (-0.27%)
AAPL   141.22 (-1.18%)
MSFT   244.65 (-0.19%)
META   113.87 (-0.22%)
GOOGL   95.15 (-1.89%)
AMZN   88.40 (+0.17%)
TSLA   173.08 (-3.75%)
NVDA   160.67 (+0.50%)
NIO   12.61 (-4.76%)
BABA   88.56 (-3.16%)
AMD   69.94 (-0.47%)
T   19.32 (+0.78%)
MU   53.50 (-0.34%)
CGC   3.22 (-10.80%)
F   13.14 (-1.05%)
GE   85.47 (+0.22%)
DIS   92.00 (-0.31%)
AMC   6.10 (-9.63%)
PYPL   74.31 (+2.88%)
PFE   50.41 (+1.41%)
NFLX   306.90 (+0.44%)
S&P 500   3,929.82 (-0.29%)
DOW   33,558.44 (-0.11%)
QQQ   280.92 (-0.27%)
AAPL   141.22 (-1.18%)
MSFT   244.65 (-0.19%)
META   113.87 (-0.22%)
GOOGL   95.15 (-1.89%)
AMZN   88.40 (+0.17%)
TSLA   173.08 (-3.75%)
NVDA   160.67 (+0.50%)
NIO   12.61 (-4.76%)
BABA   88.56 (-3.16%)
AMD   69.94 (-0.47%)
T   19.32 (+0.78%)
MU   53.50 (-0.34%)
CGC   3.22 (-10.80%)
F   13.14 (-1.05%)
GE   85.47 (+0.22%)
DIS   92.00 (-0.31%)
AMC   6.10 (-9.63%)
PYPL   74.31 (+2.88%)
PFE   50.41 (+1.41%)
NFLX   306.90 (+0.44%)
LON:RENE

ReNeuron Group - RENE Share Forecast, Price & News

GBX 12.25
-1.75 (-12.50%)
(As of 12/7/2022 04:41 PM ET)
Add
Compare
Today's Range
12
▼
13.50
50-Day Range
14
▼
28.50
52-Week Range
12
▼
94
Volume
7.08 million shs
Average Volume
247,539 shs
Market Capitalization
£7.00 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
RENE stock logo

About ReNeuron Group (LON:RENE) Stock

ReNeuron Group plc researches, develops, and commercializes cell-based therapies in the United Kingdom. The company engages in the development of CTX stem cell therapy candidate for treating stroke disability; and human retinal progenitor cell therapy that is in Phase 2 clinical trial for treating retinitis pigmentosa, a blindness-causing disease. It also develops CTX-derived exosomes that are in the pre-clinical stage, which are Nano-sized packages of information released by CTX cells. In addition, the company licenses ReNcell products. It has a collaboration agreement with University College London to conduct research into the generation of immune cells from induced pluripotent stem cells for anti-cancer cell therapies. The company was founded in 1997 and is headquartered in Pencoed, the United Kingdom.

Receive RENE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ReNeuron Group and its competitors with MarketBeat's FREE daily newsletter.

RENE Stock News Headlines

December 7, 2022 | finance.yahoo.com
ReNeuron Group (RENE): Pushing on with CustomEx in H123
December 4, 2022 | finance.yahoo.com
ReNeuron Group First Half 2023 Earnings: UK£0.056 loss per share (vs UK£0.092 loss in 1H 2022)
October 7, 2022 | marketwatch.com
ReNeuron Says New Data From CustomEx Platform Supports Monetization Strategy
October 7, 2022 | proactiveinvestors.com
ReNeuron Group data points to effectiveness of its ground-breaking technology
September 15, 2022 | marketwatch.com
ReNeuron Appoints New CFO
September 14, 2022 | proactiveinvestors.com
ReNeuron Group names John Hawkins as chief financial officer in boardroom reshuffle
August 25, 2022 | uk.finance.yahoo.com
ReNeuron Group plc (RENE.L)
August 22, 2022 | msn.com
SMALL CAP IDEA: ReNeuron finance boss says changes at biotech research firm mirror previous role
August 22, 2022 | proactiveinvestors.com
ReNeuron CEO: 'We have a great company that just needed a shake-up'
August 2, 2022 | marketwatch.com
ReNeuron Group Names CFO Catherine Isted as CEO
August 1, 2022 | lse.co.uk
EXECUTIVE CHANGES: ReNeuron promotes CFO Catherine Isted to CEO role
July 5, 2022 | seekingalpha.com
ReNeuron Group plc (RNUGF) Management on Q4 2022 Results - Earnings Call Transcript
April 13, 2022 | marketwatch.com
Stem Cell Market Size Analysis Report 2022 by Manufacturing Base Distribution, Sales Area and Product Type by Player and Forecasts to 2029
March 30, 2022 | finance.yahoo.com
ReNeuron Group PLC (RQE1.SG)
March 1, 2022 | finance.yahoo.com
Insiders who bought in the last 12 months lose an additional UK£36k as ReNeuron Group plc (LON:RENE) drops to UK£17m
February 11, 2022 | marketwatch.com
ReNeuron CEO Olav Hellebo Steps Down
January 18, 2022 | lse.co.uk
ReNeuron shares dive as it drops retinitis pigmentosa trials
January 18, 2022 | marketwatch.com
ReNeuron to Exit Retinitis Pigmentosa Therapy Trials; Shares Dive
January 11, 2022 | lse.co.uk
ReNeuron re-appoints Randolph Corteling in senior research role
December 19, 2021 | markets.businessinsider.com
ReNeuron Group plc : Director Declaration
October 26, 2021 | finance.yahoo.com
Here's Why We're Not At All Concerned With ReNeuron Group's (LON:RENE) Cash Burn Situation
October 23, 2021 | lse.co.uk
Director dealings: Reneuron Group non-executive makes share purchase
October 21, 2021 | lse.co.uk
DIRECTOR DEALINGS: Inspiration Healthcare exec sells 135,000 shares
October 11, 2021 | finanznachrichten.de
Edison Investment Research Limited: ReNeuron Group (RENE): Extension Trial to Produce Data in Q122
October 11, 2021 | marketwatch.com
ReNeuron Shares Rise on Positive Data From Exosome Drug Delivery Technology Trial
See More Headlines
Receive RENE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ReNeuron Group and its competitors with MarketBeat's FREE daily newsletter.

RENE Company Calendar

Last Earnings
7/20/2020
Today
12/07/2022
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
LON
Industry
Biotechnology
Sub-Industry
N/A
Sector
Medical
Current Symbol
LON:RENE
CUSIP
N/A
CIK
N/A
Web
www.reneuron.com
Phone
+44-20-38198400
Fax
N/A
Employees
38
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
5.68
Current Ratio
2.35
Quick Ratio
2.29

Sales & Book Value

Annual Sales
£403,000.00
Price / Sales
17.37
Cash Flow
GBX 13.13 per share
Price / Cash Flow
0.93
Book Value
GBX 17.30 per share
Price / Book
0.71

Miscellaneous

Outstanding Shares
57,146,000
Free Float
N/A
Market Cap
£7.00 million
Optionable
Not Optionable
Beta
N/A

Key Executives

  • Ms. Catherine Isted A.C.M.A.
    CEO & Exec. Director
  • Dr. John David Sinden B.A. (Age 71)
    BA, M.A., MA, Ph.D., Co-Founder & Member of Scientific Advisory Board
  • Mr. John Michael Hawkins A.C.A. (Age 56)
    CFO & Director
  • Ms. Suzanne Hancock
    Chief Operations Officer
  • Dr. Randolph Corteling Ph.D.
    Chief Scientific Officer
  • Mr. Shaun Stapleton
    Head of Regulatory Affairs and VP of Regulatory Affairs & Pharmacovigilance

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













RENE Stock - Frequently Asked Questions

How have RENE shares performed in 2022?

ReNeuron Group's stock was trading at GBX 82 at the start of the year. Since then, RENE stock has decreased by 84.8% and is now trading at GBX 12.48.
View the best growth stocks for 2022 here.

How were ReNeuron Group's earnings last quarter?

ReNeuron Group plc (LON:RENE) posted its quarterly earnings data on Monday, July, 20th. The company reported ($35.90) EPS for the quarter, topping the consensus estimate of ($50.20) by $14.30.

What other stocks do shareholders of ReNeuron Group own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ReNeuron Group investors own include 10094 (IRD.TO) (IRD), Sareum (SAR), ValiRx (VAL), IOG (IOG), Dignity (DTY), Tri-Star Resources plc (TSTR.L) (TSTR), Sirius Minerals (SXX), Collagen Solutions plc (COS.L) (COS), RenovaCare (RCAR) and ReNeuron Group (RNUGF).

What is ReNeuron Group's stock symbol?

ReNeuron Group trades on the London Stock Exchange (LON) under the ticker symbol "RENE."

How do I buy shares of ReNeuron Group?

Shares of RENE stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What is ReNeuron Group's stock price today?

One share of RENE stock can currently be purchased for approximately GBX 12.48.

How much money does ReNeuron Group make?

ReNeuron Group (LON:RENE) has a market capitalization of £7.13 million and generates £403,000.00 in revenue each year.

How can I contact ReNeuron Group?

ReNeuron Group's mailing address is Pencoed Business Park, BRIDGEND, CF35 5HY, United Kingdom. The official website for the company is www.reneuron.com. The company can be reached via phone at +44-20-38198400.

This page (LON:RENE) was last updated on 12/7/2022 by MarketBeat.com Staff